|Year : 2018 | Volume
| Issue : 2 | Page : 52-56
Drug treatment of pruritus of systemic origin
Asit Mittal1, Kapil Vyas2
1 Department of Dermatology, Venereology and Leprology, RNT Medical College, Affiliated to Rajasthan University of Health Sciences, Udaipur, Rajasthan, India
2 Department of Dermatology, Venereology and Leprology, Geetanjali Medical College, Affiliated to Geetanjali University, Udaipur, Rajasthan, India
|Date of Web Publication||31-Dec-2018|
Dr. Asit Mittal
Department of Dermatology, Venereology and Leprology, RNT Medical College, Affiliated to Rajasthan University of Health Sciences, Udaipur - 313 001, Rajasthan
Source of Support: None, Conflict of Interest: None
Pruritus is an unpleasant subjective sensation evoking a desire to scratch. It is commonly encountered in dermatological diseases but could be a signaling symptom of several systemic disorders. Chronic refractory pruritus of systemic origin is often unresponsive to antihistamines and glucocorticoids due to multiple underlying mechanisms. Holistic approach is usually needed to address the stubborn symptom.This review will focus on various topical and systemic pharmacological agents used in the management of pruritus of systemic origin.
Keywords: Itch, pruritus, review, scratch
|How to cite this article:|
Mittal A, Vyas K. Drug treatment of pruritus of systemic origin. Indian J Drugs Dermatol 2018;4:52-6
| Introduction|| |
Pruritus is an unpleasant sensation that evolved for the purpose of defense against harmful ectoparasites. Physiologically, it simulates pain in terms of genesis and transmission but evokes a different behavioral response of scratching. The itch-scratch reflex is executed locally at the spinal level with precise regulation by higher brain centers. Clinically, pruritus can be defined as localized or generalized, depending on the extent of involvement or as acute and chronic, depending on the duration of the symptom. In the past, pruritus was regarded solely due to the dermatological origin, but now, it is better understood that it can be a signaling symptom of several systemic diseases such as hepatobiliary disorders, chronic kidney disease, hematological, endocrine abnormalities, neuropsychiatric diseases, and even malignancies. This review will deal with the drug treatment of pruritus of systemic origin.
| Pruritus of Hepatobiliary Origin (Cholestatic Pruritus)|| |
Pruritus occurs in approximately one-fifth of the hepatic patients. Prevalence is greater in intrahepatic causes as compared to extrahepatic cholestasis. Several mechanisms explain pruritus in cholestatic liver disease:
- Accumulation of toxic pruritogens
- Imbalance in endogenous opioid system
- Autotaxin (ATX), mediated conversion of lysophosphatidylcholine into lysophosphatidic acid (LPA), which, in turn, correlates with the itch response.,
Commonly used antipruritic medications such as antihistamines and glucocorticoids are ineffective in cholestatic pruritus; however, partial benefits may be observed due to their sedative properties. Pruritus associated with extrahepatic bile duct obstruction responds promptly to the restoration of biliary drainage. The following drugs are frequently used:
Bile acid therapy
Drug in this class is ursodeoxycholic acid (UDCA). It is frequently used to treat cholestasis of a range of causes, including cholestasis of pregnancy and primary biliary cholangitis. In intrahepatic cholestasis of pregnancy (ICP), UDCA improved itch and liver enzymes in several randomized placebo-controlled trials. It is the preferred drug for the management of ICP. The recommended dose is 10–15 mg/kg in two to three divided doses.
Anion exchange resins
Cholestyramine, colestipol, and colesevelam are nonabsorbable anion exchange resins enhancing the intestinal excretion of pruritogens in bile. Several randomized controlled trials (RCTs) involving cholestyramine use have derived heterogeneous results. However, one small, double-blinded RCT showed a beneficial effect in ten patients, using cholestyramine 9 g daily orally. The recommended dose of cholestyramine is 4–16 g daily, initiated with 4 g administered orally before and after breakfast. Common adverse effects include bloating, constipation, malabsorption of nutrients, and coagulopathy. It can be considered as a first-line treatment in patients with hepatic pruritus.
Hepatic enzyme inducer
Drug in this class is rifampicin. It is regarded as a second-line treatment for cholestatic pruritus. It partially ablates cholestatic pruritus by the pregnane X receptor-dependent transcriptional inhibition of ATX expression. Furthermore, it may have an anti-opiate effect. It should be started at a dose of 150 mg twice daily if serum bilirubin is >3 mg/dl and 150 mg three times daily if serum bilirubin is <3 mg/dl, with gradual dose escalation to 600 mg twice daily. Rifampicin can be hepatotoxic, and liver tests should be monitored.
These are recommended as third-line therapy. The μ-opioid antagonist, naltrexone, in a daily dose of 50 mg orally is found to be effective in pruritus of hepatobiliary disease. Nalmefene (0.25–1μg/kg/day intravenously), methylnaltrexone, and naloxone may be alternative opioid antagonists to naltrexone. Possible adverse effects with these agents are opiate withdrawal-like syndrome, but this can be avoided by initiating treatment with naltrexone at a low dose of 12 mg or intravenous infusion of naloxone, followed by stepwise dose increase. Naltrexone can be hepatotoxic.
Selective serotonin reuptake inhibitor
Selective serotonin reuptake inhibitors (SSRIs) increase the threshold of itch generation. Several RCTs revealed the efficacy of sertraline in hepatic pruritus in a daily dose of 75–100 mg. Sertraline is considered the fourth-line treatment option in the management of cholestatic pruritus. Anecdotal reports of successful treatment of cholestatic pruritus include the use of intravenous lidocaine, flumecinol, antioxidants, parenteral ondansetron (5-HT3-receptor antagonist), ultraviolet B phototherapy, and androgens.
A novel approach could be inhibiting the apical sodium-dependent bile acid transporter that plays a physiological role in the absorption of the bile acid in the ileum. Several studies including Phase 2 trials have shown their possible effectiveness in the treatment of cholestatic itch. Agents inhibiting ATX or its product, LPA, may also be of interest in the future therapy of cholestatic itch.
| Uremic Pruritus|| |
Uremic pruritus (UP) is a consequence of underlying pathophysiologic alterations related to chronic kidney disease. Nearly 40% of patients with end-stage renal disease experience moderate-to-severe pruritus. There is a proposed role of several factors including increased systemic inflammation, abnormal serum parathyroid hormone, calcium and phosphorus levels, an imbalance in opiate receptors, and a neuropathic process. Additional contributors are xerosis and anemia. Therapeutic modalities available are topical and systemic agents, phototherapy, acupuncture, and surgical methods. Adequate dialysis, calcium and phosphate homeostasis, correcting anemia, and xerosis are prerequisite before shifting to antipruritic medication.
UP is often generalized in nature. Thus, it would be impractical to use topical agents. However, liberal use of emollients for adequate skin hydration is an important component of therapy. Drugs frequently used in battling UP include:
The evidence for most of the topical therapies is not of high quality; still, the following drugs find mention in the literature.
- A single-center, double-blind RCT observed superior antipruritic action of 1% pramoxine hydrochloride as compared to placebo, in patients on hemodialysis
- Cromolyn sodium (4%) relieves UP by stabilizing mast cells and indirectly inhibiting the activation of sensory nerves. Tacrolimus and calcitriol have antipruritic effects by virtue of alteration of local immunological milieu,
- Capsaicin (0.025%) is a natural alkaloid extracted from chili peppers. It alleviates uremic pruritus by depleting neuropeptides in peripheral sensory neurons which, in turn, interferes with the conduction of itch
- Topical gamma-linolenic acid relieves the uremic itch by modulating lymphokines and prostaglandin synthesis
- A recent observation found a significant reduction of uremic xerosis and pruritus with topical preparation containing structured lamellar lipids and endocannabinoids: N-acetylethanolamine and N-palmitoylethanolamine.
Systemic medications reported to be beneficial in patients with UP are exhaustive and include gabapentinoids, activated carbon, cholestyramine, opioid antagonists, thalidomide and pentoxifylline, nicergoline, a leukotriene inhibitor, and antihistamines. However, evidence for the efficacy of most of these systemic therapies is not robust and derived out of small open-label studies and case series.
- Gabapentinoids suppress UP by their neuromodulatory action mediated through binding voltage-gated calcium channels. This class includes gabapentin and pregabalin. Gabapentin is typically dosed at 50–100 mg at night. About 300 mg three times weekly for 4 weeks has also been found to be safe and effective in double-blind studies. Pregabalin is a similar drug that has been reported to reduce chronic itch in dialysis. Therapy with 75 mg of pregabalin orally twice weekly was compared, either to ondansetron or placebo, and was found effective. The only oral agents that have produced consistent results in UP are gabapentinoids.
- Activated carbon and cholestyramine may abate UP by sequestering putative pruritogens in the intestinal lumen.,
- Presuming the imbalance in opioid receptor expression as one of the mechanisms in UP. Naltrexone (μ-receptor antagonist), nalfurafine (ĸ-receptor agonist), and butorphanol (κ-agonist and μ-antagonist) have been evaluated in various clinical trials with variable efficacy,
- Thalidomide and pentoxifylline are anti-inflammatory agents with TNF-alpha antagonizing action. These agents have been found useful in refractory UP across different studies,
- As for other oral medications, few small-scale studies have shown the efficiency of ketotifen 1 mg daily and doxepin 10 mg twice daily in the treatment of UP due to their additional mast cell stabilizing property. There have been conflicting reports of the efficacy of 5-HT3 receptor antagonists (ondansetron) in UP. Uremic itch threshold can be modified using serotonin–norepinephrine reuptake inhibitors (SNRIs) (mirtazapine) and SSRIs (sertraline).
UP is associated with increased mortality. Renal transplantation is the only definitive treatment for this condition.
| Hematological Pruritus|| |
Pruritus is often associated with hematological disorders including iron deficiency, hemochromatosis (iron overloading state), myeloproliferative disorders, lymphomas, and leukemias.
- Iron deficiency may present with generalized pruritus with or without anemia and other signs of iron deficiency. Iron is an important cofactor for enzymatic activities, and its deficiency may lead to metabolic alteration and thus pruritus. The management of such pruritus includes iron supplementation in addition to treating underlying causes of iron deficiencies such as alcoholism, malabsorption, occult bleeding, and malignancies
- Pruritus in lymphoma and leukemia may imply bad prognosis but improves after radiation therapy or chemotherapy
- Aquagenic pruritus of myeloproliferative disorder is characteristically precipitated by contact with hot and cold water, sweating, and alcohol. Basophilic granulocytes play a key role in triggering the symptoms.
The recommended measures to manage pruritus in such disorders are the use of salicylates, alkalinization of bathing water, topical capsaicin treatment, systemic therapy with antihistaminic and antiserotonergic drugs (cyproheptadine, paroxetine, and pizotifen), or phototherapy. Cytoreductive therapy with agents such as hydroxyurea and interferon-alpha 21 has also been found to be effective in the control of pruritus associated with polycythemia vera.
| Endocrine Disorders|| |
- Pruritus is common in thyroid diseases. About 4%–11% of hyperthyroid patients present with pruritus which is attributed to increased skin temperature and decreased itch threshold. Treatment with antithyroid medication along with antihistamines would effectively suppress the itch. Hypothyroidism-associated xerosis is responsible for evoking pruritus which usually responds to liberal use of emollients and thyroid hormone replacement. Subtotal parathyroidectomy may improve pruritus associated with abnormal parathyroid gland activity
- Pruritus associated with diabetes mellitus has multiple mechanisms, i.e., due to bacterial and fungal infection, metabolic abnormalities, autonomic dysfunction with anhidrosis, diabetic neuropathy, and antidiabetic drugs. Judicious use of antibiotics, barrier restoration, hygroscopic emollients, and neuromodulators along with strict control of blood sugar is all that is required
- It is to be emphasized that hormonal replacement therapy in women may relieve vulvar pruritus of postmenopausal period.
| Pruritus Associated with Malignant Solid Tumors|| |
Solid malignant tumors are a relatively rare cause of pruritus. Generalized pruritus in malignancy can be multifactorial – a true paraneoplastic symptom, secondary to paraneoplastic neuropathy, a consequence of secondary skin involvement by cutaneous or noncutaneous primary tumors, or a side effect of cancer treatment. Generalized pruritus has been described in breast, colon, lung, testicular, and stomach cancers; insulinoma; gastric carcinoid; and thymoma.
Treatment of the malignancy can often help to resolve pruritus.
- Anticancer drugs and biologics can also trigger pruritus and require modification or discontinuation of medications
- Antihistamines are generally ineffective in pruritus due to solid tumors
- Kappa opioids and neuroleptics are of some use in reducing bothersome pruritus
- SSRIs such as paroxetine 20 mg daily, and SNRI such as mirtazapine 15–30 mg daily, may have a role in the management of malignant pruritus. These medicines are thought to act centrally and may take up to 2–3 weeks to become clinically beneficial
- Granisetron, a 5-HT3 receptor antagonist, has been used in a case of pruritus in advanced malignancy, where a continuous infusion (3 mg/24 h) resulted in a prompt reduction in pruritus in 2 h
- Substance P is a key mediator of pruritus, and blockade of its receptor, neurikinin-1 (NK-1), can be of some use. NK-1 receptor antagonist aprepitant had a 91% response rate, defined by >50% reduction in pruritus intensity in 45 patients with metastatic solid tumors. Aprepitant treatment has been used with success for pruritus associated with both malignant and nonmalignant conditions in at least 74 patients
- Thalidomide may be used as a last resort for the management of cancer-related pruritus in a palliative care situation.
| Neuropathic and Psychogenic Pruritus|| |
Neuropathic pruritus refers to any dysfunction along the afferent itch pathway that results in a feeling to scratch. Nearly 8%–19% of patients with chronic pruritus have an underlying neuropathic cause. Allokinesis resulting from neural sensitization is frequently associated with neuropathic itch. Disorders of the peripheral nervous system associated with neuropathic pruritus are postherpetic neuralgia, notalgia paraesthetica, brachioradial pruritus, and prurigo nodularis. Structural or functional dysfunction in the central nervous system may underlie the pruritus of transverse myelitis, syringomyelia, stroke, and multiple sclerosis.
Psychogenic itch can be defined as an itch disorder where the itch is at the center of the symptomatology and where psychological factors play an evident role in the triggering, intensity, aggravation, or persistence of the pruritus. Although a purely psychogenic itch is a rare phenomenon in dermatology clinics, diagnosis can be established after ruling out related organic causes and with aid of the French Psychodermatology Group Diagnostic Criteria.
Commonly prescribed antipruritic medicines such as antihistamines and corticosteroids have a limited role in management. Treatment options include:
- Mild-to-moderate neuropathic itch can be controlled by topical application of local anesthetic preparations (lidocaine, pramoxine, and eutectic mixtures), cooling agents (menthol), capsaicin, and strontium hydrogel
- Topical acetylsalicylic acid may be helpful in reducing itch intensity in postherpetic neuralgia
- Systemic agents are required for severe and refractory cases. These agents have a direct or indirect influence on the neural transmission by blocking either ion channels or modifying neurotransmitters level at the synapse
- The most widely used agents are gabapentinoids. Gabapentin is approved by the USFDA for the treatment of postherpetic neuralgia and is also effective for postherpetic itch and other neuropathic itches
- Additional alternatives are oxcarbazepine, SSRIs (serotonin), tricyclic antidepressants (amitriptyline), SNRIs (mirtazapine), and neurokinin receptor antagonist (aprepitant)
- About 1–4 mg of intranasal butorphanol can reduce symptoms in patients with a refractory itch. However, clinical evidence for the use of opioid agonist and antagonists for neuropathic itch is lacking
- NMDA receptor antagonist (intravenous ketamine: 0.5 mg/kg) and oral lidocaine analogs, mexiletine, are the potential therapeutic option for the treatment-refractory neuropathic itch
- For psychogenic pruritus, the drug armamentarium is the same as that for neurological itch with an addition of antipsychotic preparation for delusional disorders such as pimozide and risperidone
- Potential future treatments involve the development of agents targeting neurokinin-1 receptors, transient receptor potential channels, and Mas-related G-protein-coupled receptor.
| Conclusion|| |
Systemic diseases can be a cause of chronic intractable pruritus. Although there are a number of topical and systemic medications available for use, the evidence for a large number of these therapies is not of a very high order. The better understanding of the pathophysiology of itch will lead to a more targeted approach in the future.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al.
Clinical classification of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol 2007;87:291-4.
Metz M, Ständer S. Chronic pruritus – Pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010;24:1249-60.
Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46.
Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, et al.
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008-18, 1018.e1.
Grand'Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: A meta-analysis including non-randomized studies. J Obstet Gynaecol Can 2014;36:632-41.
Di Padova C, Tritapepe R, Rovagnati P, Rossetti S. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: Relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984;6:773-6.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94:488-93.
Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: A review. J Am Acad Dermatol 2010;63:680-8.
Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ, et al.
Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45:666-74.
Greaves MW. Itch in systemic disease: Therapeutic options. Dermatol Ther 2005;18:323-7.
Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, et al.
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: A double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 2017;389:1114-23.
Kremer AE, Bolier R, van Dijk R, Oude Elferink RP, Beuers U. Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis 2014;32:637-45.
Manenti L, Tansinda P, Vaglio A. Uraemic pruritus: Clinical characteristics, pathophysiology and treatment. Drugs 2009;69:251-63.
Young TA, Patel TS, Camacho F, Clark A, Freedman BI, Kaur M, et al.
A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009;20:76-81.
Feily A, Dormanesh B, Ghorbani AR, Moosavi Z, Kouchak M, Cheraghian B, et al.
Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: A randomized double-blind study in 60 patients. Int J Clin Pharmacol Ther 2012;50:510-3.
Duque MI, Yosipovitch G, Fleischer AB Jr., Willard J, Freedman BI. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: A randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005;52:519-21.
Jung KE, Woo YR, Lee JS, Shin JH, Jeong JU, Koo DW, et al.
Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study. J Dermatol 2015;42:800-3.
Makhlough A, Ala S, Haj-Heydari Z, Kashi Z, Bari A. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis 2010;4:137-40.
Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 2006;48:69-76.
Szepietowski JC, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options. Ther Apher Dial 2005;9:277-9.
Nofal E, Farag F, Nofal A, Eldesouky F, Alkot R, Abdelkhalik Z, et al.
Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature. J Dermatolog Treat 2016;27:515-9.
Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H, et al.
Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9.
Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J, et al.
Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: A prospective, randomized, double-blind study. Int Urol Nephrol 2015;47:161-7.
Pederson JA, Matter BJ, Czerwinski AW, Llach F. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Ann Intern Med 1980;93:446-8.
Silverberg DS, Iaina A, Reisin E, Rotzak R, Eliahou HE. Cholestyramine in uraemic pruritus. Br Med J 1977;1:752-3.
Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, et al.
Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000;11:514-9.
Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H, et al.
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-7.
Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR, et al.
Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron 1994;67:270-3.
Mettang T, Krumme B, Bohler J, Roeckel A. Pentoxifylline as treatment for uraemic pruritus – An addition to the weak armentarium for a common clinical symptom? Nephrol Dial Transplant 2007;22:2727-8.
Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, et al.
Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991;30:884-9.
Chan KY, Li CW, Wong H, Yip T, Chan ML, Cheng HW, et al.
Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. J Palliat Med 2013;16:966-70.
Valsecchi R, Cainelli T. Generalized pruritus: A manifestation of iron deficiency. Arch Dermatol 1983;119:630.
Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients. Am J Hematol 2013;88:665-9.
Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107:451-8.
Mullin GE, Eastern JS. Cutaneous signs of thyroid disease. Am Fam Physician 1986;34:93-8.
Ståhle-Bäckdahl M, Hägermark O, Lins LE, Törring O, Hilliges M, Johansson O, et al.
Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. J Intern Med 1989;225:411-5.
Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Symptom Manage 2001;21:151-68.
Sener AB, Kuscu E, Seckin NC, Gökmen O, Taner D, Cobanoglu O, et al.
Postmenopausal vulvar pruritus – Colposcopic diagnosis and treatment. J Pak Med Assoc 1995;45:315-7.
Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev 2001;27:305-12.
Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg 2011;30:107-12.
Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial. J Pain Symptom Manage 2003;26:1105-12.
Porzio G, Aielli F, Narducci F, Cannita K, Piccolo D, Marchetti P, et al.
Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. Support Care Cancer 2004;12:208-9.
Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al.
Aprepitant for management of severe pruritus related to biological cancer treatments: A pilot study. Lancet Oncol 2012;13:1020-4.
Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer 2017;17:200.
Lowney AC, McAleer MA, Kelly S, McQuillan RJ. Thalidomide therapy for pruritus in the palliative setting – A distinct subset of patients in whom the benefit may outweigh the risk. J Pain Symptom Manage 2014;48:e3-5.
Yosipovitch G, Goodkin R, Wingard EM, Bernhard J. Neuropathic pruritus. In: Yosipovitch G, Greaves M, Fleischer A, McGlone F, eds. Itch: basic mechanisms and therapy. New York: Marcel Dekker, 2004: 231-9.
Misery L, Alexandre S, Dutray S, Chastaing M, Consoli SG, Audra H, et al.
Functional itch disorder or psychogenic pruritus: Suggested diagnosis criteria from the French psychodermatology group. Acta Derm Venereol 2007;87:341-4.
Papoiu AD, Valdes-Rodriguez R, Nattkemper LA, Chan YH, Hahn GS, Yosipovitch G, et al.
A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol 2013;93:520-6.
Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997;73:123-39.
Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. In: Cowen A, Yosipovitch G, editors. Pharmacology of Itch Handbook of Experimental Pharmacology. Vol. 226. Berlin: Springer; 2015. p. 337-56.
Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006;54:527-31.
Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization. Anesth Analg 2017;124:661-74.
Wood GJ, Akiyama T, Carstens E, Oaklander AL, Yosipovitch G. An insatiable itch. J Pain 2009;10:792-7.